ALC-0159
Based on 20 publication(s) in Google Scholar
ALC-0159 presents highly mobile surface PEG chains in a dense brush-like conformation, which can form a hydrophilic barrier, reduce non-specific protein adsorption and macrophage uptake, improve colloidal stability, prolong in vivo circulation time, and affect the cellular uptake of LNPs. ALC-0159 dissociates from the surface of mRNA-LNPs under long-term mechanical oscillation stress, thereby reducing steric hindrance, inducing mRNA-LNP fusion, increasing particle size, and releasing unencapsulated mRNA.
For research use only. We do not sell to patients.
- Purity: 99.93%
- CAS No.: 1849616-42-7
- Formula: (C2H4O)nC31H63NO2
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) ALC-0159
More- Science. 2026 Mar 5;391(6789):edau9394. [Abstract]
- Mol Cancer. 2025 Jan 13;24(1):12. [Abstract]
- Mater Today. 2026 May 22;98:103389.
- ACS Nano. 2023 Sep 12;17(17):17554-17567. [Abstract]
- Adv Sci (Weinh). 2024 Sep;11(35):e2404590. [Abstract]
- J Control Release. 2025 Aug 10:384:113907. [Abstract]
- Small Methods. 2025 Jun;9(6):e2401712. [Abstract]
- NPJ Vaccines. 2025 Aug 14;10(1):193. [Abstract]
- Mol Ther Nucleic Acids. 2026 Mar 5;37(2):102886. [Abstract]
- Biomacromolecules. 2025 Jun 9;26(6):3563-3575. [Abstract]
- Eur J Pharm Biopharm. 2026 Jun 9:115146. [Abstract]
- Nanomedicine. 2024 Jun:58:102745. [Abstract]
- J Gen Virol. 2026 Apr;107(4). [Abstract]
- Vaccines. 2024 Jul 9;12(7):757. [Abstract]
- Immunol Cell Biol. 2026 Mar 12. [Abstract]
- bioRxiv. 2026 Jul 10.
- bioRxiv. 2026 May 4.
- bioRxiv. 2025 Jun 17.
- Research Square Preprint. 2023 Sep 12.
- bioRxiv. 2023 Jun 10.
Customer Validation & Images
-
Flow Cytometry
-
Flow Cytometry
-
Bio/Physico-chemical Assay
Biological Activity
ALC-0159 (GMP) can serve as a PEG-lipid component for the preparation of mRNA-loaded LNPs and MSC-Hyb NPs derived from extracellular vesicles of human mesenchymal stem cells; such LNPs are capable of delivering COL1A1 mRNA to diseased human tendon stem/progenitor cells (TSPCs)[1].
ALC-0159 (GMP) achieves 90% PEG coating efficiency on intact COMIRNATY mRNA‑LNP, and the PEG chains on the LNP surface have high mobility; it forms a dense brush‑like PEG conformation on the LNP surface[2].
ALC-0159 (GMP) (under shaking‑induced mechanical stress) exhibits decreased PEG signal and mobility on mRNA‑LNPs, triggers LNP aggregation and particle size increment, forms large liposome‑like structures accompanied by free mRNA release, which indicates the detachment of ALC‑0159 from the LNP surface[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 1849616-42-7
-
Appearance Solid
-
Formula (C2H4O)nC31H63NO2
-
Color White to off-white
-
SMILES
CCCCCCCCCCCCCCN(C(COCCOC)=O)CCCCCCCCCCCCCC.[n]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (20)
-
Journal Impact Factor
-
Most Recent
-
Science
Single intramuscular injection of self-amplifying RNA of Nppa to treat myocardial infarction. [Abstract]2026 Mar 5;391(6789):edau9394. PMID: 41785353 -
Mol Cancer
2025 Jan 13;24(1):12. PMID: 39806486
ALC-0159 purchased from MedChemExpress. Usage Cited in: Mol Cancer. 2025 Jan 13;24(1):12. [Abstract]
LNP-M with DMG-PEG 2000, ALC-0159, or DSPE to deliver pGFP.
ALC-0159 purchased from MedChemExpress. Usage Cited in: Mol Cancer. 2025 Jan 13;24(1):12. [Abstract]
LNP-M with DMG-PEG 2000, ALC-0159, or DSPE to deliver pGFP.
-
-
ACS Nano
Enhanced Local Delivery of Engineered IL-2 mRNA by Porous Silica Nanoparticles to Promote Effective Antitumor Immunity. [Abstract]2023 Sep 12;17(17):17554-17567. PMID: 37643221 -
Adv Sci (Weinh)
A Single-Dose mRNA Vaccine Employing Porous Silica Nanoparticles Induces Robust Immune Responses Against the Zika Virus. [Abstract]2024 Sep;11(35):e2404590. PMID: 39010673 -
J Control Release
Functional lipid nanoparticles for safe delivery of macromolecular antibiotics to gram-negative bacteria. [Abstract]2025 Aug 10:384:113907. PMID: 40451556 -
Small Methods
Cholesterol-Derived Mannosylated Polypeptide-Formed Lipid Nanoparticles for Efficient in Vivo mRNA Delivery. [Abstract]2025 Jun;9(6):e2401712. PMID: 40256901 -
NPJ Vaccines
A self-amplifying mRNA vaccine expressing PRV gD induces robust immunity against virulent mutants. [Abstract]2025 Aug 14;10(1):193. PMID: 40813770 -
Mol Ther Nucleic Acids
A transferable SARS-CoV-2 IRES module enables dual translation initiation for enhanced antigen expression in COVID-19 mRNA vaccines. [Abstract]2026 Mar 5;37(2):102886. PMID: 41883582 -
Biomacromolecules
Replacing PEG-Lipid with Amphiphilic Polycarbonates in mRNA-Loaded Lipid Nanoparticles: Impact of Polycarbonate Structure on Physicochemical and Transfection Properties. [Abstract]2025 Jun 9;26(6):3563-3575. PMID: 40347133 -
Eur J Pharm Biopharm
Interactions between mRNA lipid nanoparticles and immune cells in fresh human whole blood. [Abstract]2026 Jun 9:115146. PMID: 42264006 -
Nanomedicine
Quantitative analysis of mRNA-lipid nanoparticle stability in human plasma and serum by size-exclusion chromatography coupled with dual-angle light scattering. [Abstract]2024 Jun:58:102745. PMID: 38499167
ALC-0159 purchased from MedChemExpress. Usage Cited in: Nanomedicine. 2024 Jun:58:102745. [Abstract]
LC-MS/MS quantitation of mRNA-LNP composition during degradation in serum and plasma. (A) Overlaid PRM chromatograms of cholesterol (369.65 → 147.16), DSPC (790.82 → 184.13), ALC-0315 (766.91 → 510.62), and ALC-0159 (0.1 nM) (1184.10 → 494.62). Quantities injected: 1, 2, 4 and 8 pmol of DSPC, ALC-0315 and ALC-0159; 10, 20, 40 and 80 pmol of cholesterol.
-
J Gen Virol
Broadly neutralizing monoclonal antibodies derived from mRNA LNP immunization exhibit potent neutralizing ability against JN.1, KP.3.1.1 and XEC new Omicron variants. [Abstract]2026 Apr;107(4). PMID: 42030071 -
Vaccines
Immunogenic Comparison of Nucleic Acid-Based Vaccines Administered by Pyro-Drive Jet Injector. [Abstract]2024 Jul 9;12(7):757. PMID: 39066395 -
Immunol Cell Biol
2026 Mar 12. PMID: 41819108 -
-
-
-
-
Solvent & Solubility
DMSO : 100 mg/mL (Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Ethanol : ≥ 50 mg/mL
* "≥" means soluble, but saturation unknown.
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL; Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL; Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
ALC-0159 Related Classifications
HY-138300 Related Classifications
Powered by Bioz